These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 35181565)

  • 1. UNOS Down-Staging Criteria for Liver Transplantation of Hepatocellular Carcinoma: Systematic Review and Meta-Analysis of 25 Studies.
    Tan DJH; Lim WH; Yong JN; Ng CH; Muthiah MD; Tan EX; Xiao J; Lim SY; Pin Tang AS; Pan XH; Kabir T; Bonney GK; Sundar R; Syn N; Kim BK; Dan YY; Noureddin M; Loomba R; Huang DQ
    Clin Gastroenterol Hepatol; 2023 Jun; 21(6):1475-1484. PubMed ID: 35181565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. National Experience on Down-Staging of Hepatocellular Carcinoma Before Liver Transplant: Influence of Tumor Burden, Alpha-Fetoprotein, and Wait Time.
    Mehta N; Dodge JL; Grab JD; Yao FY
    Hepatology; 2020 Mar; 71(3):943-954. PubMed ID: 31344273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver Transplantation Outcomes in a U.S. Multicenter Cohort of 789 Patients With Hepatocellular Carcinoma Presenting Beyond Milan Criteria.
    Kardashian A; Florman SS; Haydel B; Ruiz RM; Klintmalm GB; Lee DD; Taner CB; Aucejo F; Tevar AD; Humar A; Verna EC; Halazun KJ; Chapman WC; Vachharajani N; Hoteit M; Levine MH; Nguyen MH; Melcher ML; Langnas AN; Carney CA; Mobley C; Ghobrial M; Amundsen B; Markmann JF; Sudan DL; Jones CM; Berumen J; Hemming AW; Hong JC; Kim J; Zimmerman MA; Nydam TL; Rana A; Kueht ML; Fishbein TM; Markovic D; Busuttil RW; Agopian VG
    Hepatology; 2020 Dec; 72(6):2014-2028. PubMed ID: 32124453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. National Experience on Waitlist Outcomes for Down-Staging of Hepatocellular Carcinoma: High Dropout Rate in All-Comers.
    Huang AC; Dodge JL; Yao FY; Mehta N
    Clin Gastroenterol Hepatol; 2023 Jun; 21(6):1581-1589. PubMed ID: 36038129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Downstaging Outcomes for Hepatocellular Carcinoma: Results From the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) Consortium.
    Mehta N; Frenette C; Tabrizian P; Hoteit M; Guy J; Parikh N; Ghaziani TT; Dhanasekaran R; Dodge JL; Natarajan B; Holzner ML; Frankul L; Chan W; Fobar A; Florman S; Yao FY
    Gastroenterology; 2021 Nov; 161(5):1502-1512. PubMed ID: 34331914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are There Upper Limits in Tumor Burden for Down-Staging of Hepatocellular Carcinoma to Liver Transplant? Analysis of the All-Comers Protocol.
    Sinha J; Mehta N; Dodge JL; Poltavskiy E; Roberts J; Yao F
    Hepatology; 2019 Oct; 70(4):1185-1196. PubMed ID: 30779440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk Factors and Center-Level Variation in Hepatocellular Carcinoma Under-Staging for Liver Transplantation.
    Mahmud N; Hoteit MA; Goldberg DS
    Liver Transpl; 2020 Aug; 26(8):977-988. PubMed ID: 32363720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. International study on the outcome of locoregional therapy for liver transplant in hepatocellular carcinoma beyond Milan criteria.
    Degroote H; Piñero F; Costentin C; Notarpaolo A; Boin IF; Boudjema K; Baccaro C; Chagas AL; Bachellier P; Ettorre GM; Poniachik J; Muscari F; Di Benedetto F; Duque SH; Salame E; Cillo U; Gadano A; Vanlemmens C; Fagiuoli S; Rubinstein F; Burra P; Cherqui D; Silva M; Van Vlierberghe H; Duvoux C;
    JHEP Rep; 2021 Oct; 3(5):100331. PubMed ID: 34485882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Downstaging hepatocellular carcinoma: A systematic review and pooled analysis.
    Parikh ND; Waljee AK; Singal AG
    Liver Transpl; 2015 Sep; 21(9):1142-52. PubMed ID: 25981135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcomes of hepatocellular carcinoma that underwent chemoembolization for bridging or downstaging.
    Affonso BB; Galastri FL; da Motta Leal Filho JM; Nasser F; Falsarella PM; Cavalcante RN; de Almeida MD; Felga GEG; Valle LGM; Wolosker N
    World J Gastroenterol; 2019 Oct; 25(37):5687-5701. PubMed ID: 31602168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Downstaging hepatocellular carcinoma before liver transplantation: A multicenter analysis of the "all-comers" protocol in the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) consortium.
    Natarajan B; Tabrizian P; Hoteit M; Frenette C; Parikh N; Ghaziani T; Dhanasekaran R; Guy J; Shui A; Florman S; Yao FY; Mehta N
    Am J Transplant; 2023 Nov; 23(11):1771-1780. PubMed ID: 37532179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of the prognostic power of the RETREAT score for hepatocellular carcinoma recurrence using the UNOS database.
    Mehta N; Dodge JL; Roberts JP; Yao FY
    Am J Transplant; 2018 May; 18(5):1206-1213. PubMed ID: 29068145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Simple Measure of Hepatocellular Carcinoma Burden Predicts Tumor Recurrence After Liver Transplantation: The Recurrent Hepatocellular Carcinoma-Initial, Maximum, Last Classification.
    Vutien P; Dodge J; Bambha KM; Nordstrom EM; Gralla J; Campbell K; Levek C; Nydam T; Fix O; Ioannou G; Biggins SW
    Liver Transpl; 2019 Apr; 25(4):559-570. PubMed ID: 30706653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Excellent Outcomes of Liver Transplantation Following Down-Staging of Hepatocellular Carcinoma to Within Milan Criteria: A Multicenter Study.
    Mehta N; Guy J; Frenette CT; Dodge JL; Osorio RW; Minteer WB; Roberts JP; Yao FY
    Clin Gastroenterol Hepatol; 2018 Jun; 16(6):955-964. PubMed ID: 29175528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiological-histopathological discordance in patients transplanted for HCC and its impact on post-transplant outcomes.
    Mohamed IB; Ismail MS; El Sabagh A; Afifi Abdelwahab AM; Polychronopoulou E; Kuo YF; Hassan M; Goss JA; Kanwal F; Jalal PK
    Cancer Med; 2023 Jul; 12(14):15011-15025. PubMed ID: 37326440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic performance of gadoxetic acid-enhanced liver MR imaging in the detection of HCCs and allocation of transplant recipients on the basis of the Milan criteria and UNOS guidelines: correlation with histopathologic findings.
    Lee DH; Lee JM; Baek JH; Shin CI; Han JK; Choi BI
    Radiology; 2015 Jan; 274(1):149-60. PubMed ID: 25203131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of loco-regional therapy for down-staging of hepatocellular carcinoma prior to liver transplantation.
    Shi XJ; Jin X; Wang MQ; Wei LX; Ye HY; Liang YR; Luo Y; Dong JH
    Hepatobiliary Pancreat Dis Int; 2011 Apr; 10(2):143-50. PubMed ID: 21459720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recurrent hepatocellular carcinoma after liver transplant: identifying the high-risk patient.
    Nissen NN; Menon V; Bresee C; Tran TT; Annamalai A; Poordad F; Fair JH; Klein AS; Boland B; Colquhoun SD
    HPB (Oxford); 2011 Sep; 13(9):626-32. PubMed ID: 21843263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transplantation vs resection for hepatocellular carcinoma with compensated liver function after downstaging therapy.
    Lei JY; Yan LN; Wang WT
    World J Gastroenterol; 2013 Jul; 19(27):4400-8. PubMed ID: 23885153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alpha-fetoprotein-adjusted-to-HCC-size criteria are associated with favourable survival after liver transplantation for hepatocellular carcinoma.
    Meischl T; Rasoul-Rockenschaub S; Győri G; Scheiner B; Trauner M; Soliman T; Berlakovich G; Pinter M
    United European Gastroenterol J; 2021 Mar; 9(2):209-219. PubMed ID: 32741316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.